Drugs / BAY1093884
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03996486 | Oct 2019 → May 2020 | hemophilia | Bayer | Withdrawn | No outcome recorded |
| Phase 1 | NCT03481946 | May → Oct 2018 | hemophilia A, hemophilia B | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02571569 | Oct 2015 → Jul 2018 | hemophilia A, hemophilia B | Bayer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03597022 | Jul 2018 → Oct 2019 | hemophilia | Bayer | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY1093884 | “Befovacimab (BAY1093884)” NCT03597022 ↗ |
| Known as | Befovacimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03597022 ↗ |
| Action | Inhibit | “antibody blocking the endogenous tissue factor pathway inhibitor (TFPI)” NCT03996486 ↗ |
| Modality | Monoclonal antibody | “Human monoclonal immunoglobulin G2 antibody” NCT03996486 ↗ |
| Route | Intravenous | “Drug will be administered via IV infusion over 1 hour and SC injection.” NCT02571569 ↗ |
| Route | Subcutaneous | “Drug will be administered via IV infusion over 1 hour and SC injection.” NCT02571569 ↗ |
| Target | TFPI | “blocking the endogenous tissue factor pathway inhibitor (TFPI)” NCT03996486 ↗ |